Clinical trial data can be remarkably (and unnecessarily) difficult to read. Companies spin, short-sellers hawk, and everyone else is left swimming through the muck. But there is an art to reading scientific results — and you can learn it.

STAT national biotech columnist Adam Feuerstein and STAT senior science writer Sharon Begley shared tips of the trade in this subscriber-only webinar. They offered their recommendations on what to look for — and what not to fall for — when trying to make sense of clinical trial data.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • Very informative and interesting webinar.
    Nice presentation.
    I need to look at those time to progression/event charts
    and post-hoc analyses much more carefully in future.
    Thanks guys!

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy